DaTSCAN Aids Diagnosis of Dementia with Lewy Bodies
DaTscan (ioflupane I 123 injection; GE Healthcare) was found to improve a physician's ability to definitively diagnose patients with dementia with Lewy bodies (DLB) and increase their confidence in doing so, according to data presented at the XXI World Congress of Neurology.
DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. It is a Schedule II controlled substance imaging agent that works by binding to DaT in the brain.
A multicenter, randomized, open-label, comparative clinical trial evaluated the impact of DaTscan SPECT imaging on the clinical diagnosis of dementia and physician confidence of that diagnosis in patients with possible DLB who underwent DaTscan imaging (n=114) compared to the control group (n=56). Research data showed the following:
- A higher proportion of patients who underwent DaTscan SPECT imaging had a change in diagnostic category after 8 weeks (61% vs. 4%; P< 0.0001) and 24 weeks (71% vs. 16%, P<0.0001)
- Significantly more patients in the imaging group were given more confident diagnoses during follow-up
- Clinicians also reported that they were more likely to change the diagnostic category if the DaTscan image was abnormal (82%) than if the result was normal (48%)
- The result of a DaTscan image, in combination with the clinical features, contributed significantly to a change in dementia diagnostic category
Igor Grachev, MD, Medical Director of GE Healthcare Life Sciences concluded that when DaTscan SPECT imaging is combined with other core diagnostic features, it “has the ability to facilitate a more certain confident diagnosis.”
DaTscan is already approved to assist in the evaluation of adult patients with suspected Parkinsonian syndromes and may be used to help differentiate essential tremor vs. tremor due to Parkinsonian syndromes.
For more information call (800) 558-5120 or visit DaTscan.com.